Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2024-02-15 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It details multiple repurchases of shares over a period, including dates, quantities, and prices. The document references compliance with the Main Board Listing Rules and GEM Listing Rules of the Stock Exchange of Hong Kong. It is a regulatory disclosure about share repurchases and changes in issued shares, not a financial report or earnings release. The content fits the description of a 'Transaction in Own Shares' filing, which reports the company's buyback activities. The document length is substantial and contains detailed transactional data, confirming it is the report itself, not just an announcement of a report.
2024-02-15 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It details multiple repurchases of shares over various dates, including quantities and prices, and confirms compliance with listing rules. The document is a regulatory disclosure about share repurchases, not a financial report or earnings release. It fits the description of a 'Transaction in Own Shares' filing, which reports on the company's buyback activities. The document length is about 13,496 characters, containing detailed transactional data, not just an announcement or certification. Therefore, the appropriate classification is POS (Transaction in Own Shares).
2024-02-14 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed tables of repurchases of shares, dates, quantities, prices, and confirmations of compliance with listing rules on the Stock Exchange of Hong Kong. The content focuses on reporting share repurchase transactions and changes in issued shares, consistent with regulatory disclosure requirements for share buybacks. There is no indication of a full financial report, earnings release, or management discussion. The document is a regulatory disclosure about transactions in the company's own shares, specifically repurchases. Therefore, the document fits the category of 'Transaction in Own Shares' (POS). The document length (13,376 characters) and detailed transactional data support this classification with high confidence.
2024-02-09 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It details multiple repurchases of shares over various dates, including quantities and prices, and confirms compliance with listing rules of the Stock Exchange of Hong Kong. The content is focused on reporting share repurchase transactions and capital changes, not on financial results, management commentary, or other report types. The document is about share repurchase disclosures, which aligns with the category for reporting company buying back its own shares. Therefore, the appropriate classification is 'Transaction in Own Shares' (POS). The document length is sufficient and contains detailed transactional data, confirming it is not merely an announcement or certification.
2024-02-08 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed tables of repurchases of shares on various dates, confirming compliance with listing rules of the Stock Exchange of Hong Kong. The content focuses on share repurchase transactions and confirmations related to these capital changes. There are no financial statements, earnings data, or management discussion. The document is a regulatory disclosure about share capital changes and repurchases, fitting the category of Transaction in Own Shares (POS). The document length (13,141 characters) supports it being a full disclosure rather than a brief announcement or certification. Therefore, the appropriate classification is POS with high confidence.
2024-02-07 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks for Ascletis Pharma Inc. It includes detailed tables of repurchases of shares over various dates, confirming compliance with listing rules of the Stock Exchange of Hong Kong (SEHK). The document is a regulatory disclosure about share repurchases and changes in issued shares, not a financial report or earnings release. It is a formal notification of transactions in the company's own shares (share buybacks). Therefore, the document fits the category of 'Transaction in Own Shares' (POS). The document length is substantial and contains detailed transactional data, supporting this classification with high confidence.
2024-02-06 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.